Gastrointestinal Cancer

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in November 2025 spanning tumor types.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

Jose Trevino, MD, discusses how immunotherapy and precision medicine approaches may advance treatment for patients with immune-resistant PDAC.

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Jose Trevino, MD, discusses unmet needs in PDAC, highlighting early detection and multidisciplinary care amid Pancreatic Cancer Awareness Month.

The FDA approved durvalumab plus FLOT for the perioperative treatment of resectable gastric and gastroesophageal junction cancers.

OBI-902 received orphan drug designation from the FDA for the treatment of patients with cholangiocarcinoma.

Shubham Pant, MD, MBBS, and Ryan W. Huey, MD, MS, discuss OXPHOS pathway inhibition in pancreatic cancer with lixumistat.

DPTX3186, a first-in-class oral condensate modulator, has received FDA fast track designation in gastric cancer.

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.

The phase 3 PEAK trial met its primary PFS end point with bezuclastinib plus sunitinib in imatinib-resistant/intolerant gastrointestinal stromal tumors.

Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.

Treatment with 177Lu-edotreotide was linked to improvements in PFS and ORR across subgroups of patients with SSTR-positive GEP-NETs.

Rohit Thummalapalli, MD, discusses the treatment paradigm for patients with GEP-NETs and the role of Lutetium Lu 177 dotatate across lines of therapy.

Jaume Capdevila, MD, PhD, discusses the potential for 177Lu-edotreotide for the treatment of patients with neuroendocrine tumors.

Belzutifan-based combinations meet end points in RCC, imaging agent under review for SSTR-positive neuroendocrine tumors, and more.

OncLive® and the Ruesch Center at Georgetown Lombardi announce the 2025 Luminary Award winners in gastrointestinal cancers.

The FDA set a March 29, 2026, PDUFA date for LNTH-2501, a PET imaging agent targeting SSTR-positive neuroendocrine tumors.

The FDA granted orphan drug designation to DPTX3186 in gastric cancer.

Experts discuss how AI can diagnose cancer from standard H&E slides while accounting for slide quality differences to support broader clinical use.

Revisit the most intriguing GI cancer data from the 2025 ESMO Congress.